ReviewThe journal of headache and pain2008
Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system.
Review in The journal of headache and pain, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07542340 (Effect of Osteopathic Intervention on Migraine), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Osteopathic Intervention on Migraine: A Randomised Controlled Trial
Who cites it
22 citing papers in PubMed, 67 citations in OpenAlex.
- Middle meningeal artery embolization for migraine: A review.Surgical neurology international · 2025Review
- Association Between Migraine and Frailty Among Middle-Aged and Older Adults: A Cross-Sectional Study Based on CHARLS.Pain research & management · 2025Article
- Cardiovascular Disease and Migraine: Are the New Treatments Safe?Current pain and headache reports · 2022Review
- The trigeminal system: The meningovascular complex- A review.Journal of anatomy · 2021Review
- Neuropeptide changes in an improved migraine model with repeat stimulations.Translational neuroscience · 2021Article
- Optimising migraine treatment: from drug-drug interactions to personalized medicine.The journal of headache and pain · 2019Review
- Article
- Nitroglycerin enhances the propagation of cortical spreading depression: comparative studies with sumatriptan and novel kynurenic acid analogues.Drug design, development and therapy · 2017Article
- Serum MicroRNA Signatures in Migraineurs During Attacks and in Pain-Free Periods.Molecular neurobiology · 2016Article
- Valproate ameliorates nitroglycerin-induced migraine in trigeminal nucleus caudalis in rats through inhibition of NF-кB.The journal of headache and pain · 2016Article
- Development of anti-migraine therapeutics using the capsaicin-induced dermal blood flow model.British journal of clinical pharmacology · 2015Review
- Efficacy of Pulsed Radiofrequency on Cervical 2-3 Posterior Medial Branches in Treating Chronic Migraine: A Randomized, Controlled, and Double-Blind Trial.Evidence-based complementary and alternative medicine : eCAM · 2015Article
- Dural administration of inflammatory soup or Complete Freund's Adjuvant induces activation and inflammatory response in the rat trigeminal ganglion.The journal of headache and pain · 2015Article
- Quinoline derivatives: candidate drugs for a class B G-protein coupled receptor, the calcitonin gene-related peptide receptor, a cause of migraines.CNS & neurological disorders drug targets · 2014Article
- Sumatriptan inhibits TRPV1 channels in trigeminal neurons.Headache · 2012Article
- Triptans for the management of migraine.Drugs · 2010Review
- Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine.CNS drugs · 2010Article
- New drugs for migraine.The journal of headache and pain · 2009Review
- Migraine pain: reflections against vasodilatation.The journal of headache and pain · 2009Review
- Future drugs for migraine.Internal and emergency medicine · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary headaches such as migraine are among the most prevalent neurological disorders, affecting up to one-fifth of the adult population. The scientific work in the last decade has unraveled much of the pathophysiological background of migraine, which is now considered to be a neurovascular disorder. It has been discovered that the trigemino-cerebrovascular system plays a key role in migraine headache pathophysiology by releasing the potent vasodilator calcitonin gene-related peptide (CGRP). This neuropeptide is released in parallel with the pain and its concentration correlates well with the intensity of the headache. The development of drugs of the triptan class has provided relief for the acute attacks but at the cost of, mainly cardiovascular, side effects. Thus, the intention to improve treatment led to the development of small CGRP receptor antagonists such as olcegepant (BIBN4096BS) and MK-0974 that alleviate the acute migraine attack without acute side events. The purpose of this review is to give a short overview of the pathological background of migraine headache and to illustrate the mechanisms behind the actions of triptans and the promising CGRP receptor blockers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.